


CLAIMS

[Claim 1]

A crystal of (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide, wherein the crystal has a diffraction peak at the diffraction angle ($2\theta \pm 0.2^\circ$) of 5.8° , 6.4° , 8.0° , 10.1° and 12.8° in powder X-ray diffraction.



[Claim 2]

The crystal according to claim 1, wherein the crystal further has diffraction peaks at the diffraction angles ($2\theta \pm 0.2^\circ$) of 14.2° , 16.0° , 18.9° , 19.7° and 23.1° in powder X-ray diffraction.

[Claim 3]

A crystal of (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide, wherein the crystal has a peak at the chemical shift ($\delta \pm 0.5$ ppm) of 134.0 ppm, 141.1 ppm, 154.7 ppm, 158.1 ppm and 165.1 ppm in solid state ^{13}C NMR spectrum.

[Claim 4]

The crystal according to claim 3, wherein the crystal further has peaks at the chemical shifts ($\delta \pm 0.5$ ppm) of 12.6 ppm, 55.5 ppm and 118.5 ppm in solid state ^{13}C NMR spectrum.

[Claim 5]

A pharmaceutical composition comprising a crystal according to any one of claims 1 to 4.